BioCryst Pharmaceuticals (BCRX) vs Bausch Health Companies (BHC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioCryst Pharmaceuticals (BCRX) has outperformed Bausch Health Companies (BHC) over the past year, gaining 13.9% versus a loss of 4.7%. Over five years, BCRX leads with a -45.2% price change compared with -78.8% for BHC. Bausch Health Companies is the larger company by market cap ($2.26 billion vs $2.12 billion), about 1.1 times the size.
On valuation, Bausch Health Companies trades at a lower forward P/E (1.4x vs 8.8x for BioCryst Pharmaceuticals).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCRX | BHC |
|---|---|---|
| Share price | $8.29 | $6.04 |
| Market cap | $2.12B | $2.26B |
| 1-day change | -1.31% | -1.79% |
| YTD return | +6.28% | -13.09% |
| 1-year return | +13.87% | -4.73% |
| 5-year return | -45.21% | -78.80% |
| Forward P/E | 8.82 | 1.44 |
| EPS (TTM) | $-1.40 | $-2.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.22 | $8.00 |
| 52-week low | $6.00 | $4.33 |
| Distance from 52-week high | -26.11% | -24.50% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +150.06% | +24.17% |
| Average volume | 4.13M | 3.24M |
| Shares outstanding | 255.54M | 373.99M |
| Employees | 435 | 20,300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCRX has outperformed BHC by 18.6 percentage points over the past year.
About BioCryst Pharmaceuticals
BCRX stock →BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 435 employees
About Bausch Health Companies
BHC stock →Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.
Health Care · Biotechnology: Pharmaceutical Preparations · 20,300 employees
BCRX vs BHC FAQ
Which is bigger, BioCryst Pharmaceuticals or Bausch Health Companies?
Bausch Health Companies (BHC) is larger, with a market capitalization of $2.26B compared with $2.12B for BioCryst Pharmaceuticals (BCRX).
Which stock has performed better over the past year, BCRX or BHC?
BCRX returned +13.87% over the past 12 months, compared with -4.73% for BHC (price return, excluding dividends). Past performance does not predict future results.
Are BioCryst Pharmaceuticals and Bausch Health Companies in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for BioCryst Pharmaceuticals and Biotechnology: Pharmaceutical Preparations for Bausch Health Companies.